Investigating the gut microbiome's role in antibiotic-resistant infections after lung or liver transplants
Official title: The Gut Microbiome in Carbapenem-Resistant Enterobacteriaceae Colonization, Persistence, Infection, and Tolerance after Lung or Liver Transplantation
Funded at University of Pittsburgh at Pittsburgh · NIH-11006352 · Data updated 2026-11-12
This study is looking at how the bacteria in your gut might affect the presence of tough-to-treat infections in people who have had lung or liver transplants, with the goal of finding ways to better manage antibiotic resistance for these patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | February 22, 2021 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $179,145 |
| NIH project number | 5K23AI154546-05 |
| Project ID | NIH-11006352 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have received a lung or liver transplant and are at risk for infections caused by carbapenem-resistant bacteria.
✕Less likely to help
Patients who have not undergone lung or liver transplantation or those without risk factors for CRE infections may not benefit from this research.
What this research studies
This research focuses on understanding how the gut microbiome influences the colonization and persistence of carbapenem-resistant Enterobacteriaceae (CRE) in patients who have undergone lung or liver transplantation. The study aims to identify genetic traits of CRE that contribute to infections and tolerance to antibiotics, as well as the gut microbiota changes associated with these conditions. By analyzing stool samples and patient data, researchers hope to uncover patterns that could lead to better management of antibiotic resistance in transplant recipients.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating antibiotic-resistant infections in transplant patients.
How similar studies have gone: Previous research has shown promising results in understanding the gut microbiome's role in antibiotic resistance, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Haidar, Ghady — University of Pittsburgh at Pittsburgh
- Study coordinator: Haidar, Ghady
Related research
Other NIH-funded projects on the same topics.
-
Multi-agent AI to annotate enzymes in the human gut microbiome
A team at a major university will build an AI system that automatically curates and labels the functions of enzymes in the human gut microbiome to speed up understanding their health effects.
-
Mapping how gut bacteria transform drugs
Scientists will study how the gut microbiome changes thousands of drugs into new forms, which could affect how well a medicine works or whether it causes side effects.
-
Aflatoxin exposure and child growth in Guatemala
A study in rural Guatemala will track how exposure to aflatoxin relates to growth and gut health in young children.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
How gut bacteria affect how cancer drugs work
This project looks at how the bacteria in your gut might change how well and with what side effects fluoropyrimidine cancer drugs like 5-FU work in people.
-
Gut bacteria and cancer drugs: how your gut may change chemotherapy effectiveness
This project studies how the gut microbiome might affect how well certain chemotherapy drugs work and their side effects in people with cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.